BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 08 gen, 2012
    Sommario
    A Strategic International Health Care Event (10th February 2012, Milano - Italy)
    Italian Biotech meets Investors in Milan (BioInItaly, April 18-19)
    UK–Italy Business Awards Ceremony
  • 02 dic, 2011
    Sommario
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 03 nov, 2011
    Sommario
    Fast Forward, Juvenile Diabetes Research Foundation and Axxam renew their partnership to accelerate development of treatments for multiple sclerosis and type 1 diabetes
    Adienne’s Mubodina patented by EPO and USPTO
    Genovax completes the Phase I/II clinical study for GX301
    MolMed expands Phase III trial of NGR-hTNF for the treatment of mesothelioma in the United States
    Phase II study evaluating Abraxane® clinical potential in patients with advanced pancreatic cancer published in the Journal of Clinical Oncology online
    Independent radiology assessment panel results confirm statistical significance of response and progression endpoints of Cell Therapeutics’ Pixantrone PIX301 Pivotal Trial
  • 03 ott, 2011
    Sommario
    Tools of Science, new tool for life science professionals
    NicOx: new preclinical data for NCX 6560
    Key European patent for MolMed’s TK cell therapy
    Axxam receives funding for the development of compounds for prevention treatment of disability in Multiple Sclerosis
    MolMed presents new data from four clinical trials on NGR-hTNF at European Multidisciplinary Cancer Congress
    Axxam and Polyphor participate in a Research Partnership for the Treatment of Type-2 Diabetes Funded by the EU
  • 29 lug, 2011
    Sommario
    A Further Milestone Reached in the Collaboration Between Siena Biotech and Roche
    Siena Biotech S.p.A
    Monitoring the lipid composition of cell culture membranes: a special price for ReMembrane
  • 07 giu, 2011
    Sommario
    METGEN and SPRIN: Biocatalysis for the Future
    MolMed: Results of three Phase II trials in lung cancer indications confirm safety and antitumour activity of NGR-hTNF
    Areta successfully selected for Italia degli Innovatori 2011/2012
  • 05 mag, 2011
    Sommario
    Siena Biotech announces Start of Phase II Studies with SEN0014196 for Huntington’s Disease
    NicOx withdraws its marketing authorization application for naproxcinod in Europe
    Otsuka establishes Otsuka Pharmaceutical Italy S.r.l.
    Cell Therapeutics acquires exclusive marketing and co-development rights in the Americas to Chroma Therapeutics’Tosedostat
  • 03 mag, 2011
    Sommario
    Siena Biotech S.p.A. announces Start of Phase II Studies with SEN0014196 for Huntington’s Disease
    NicOx and Ferrer enter into option agreement for naproxcinod
    MolMed and Fondazione Telethon to collaborate on gene therapy for six rare diseases
    Bio3 Research S.r.l. appoints V.I.Pharma as exclusive distributor of the dietary supplement Biocysan in Greece
    Archimede R&D honoured by the 2011 Environment Enterprise Award
  • 15 mar, 2011
    Sommario
    Aptuit optimizes use of dried blood spot assays for customers
    ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
  • 01 mar, 2011
    Sommario
    Toscana Life Sciences Foundation and Kedrion announce a collaboration agreement
    Siena Biotech and Pierrel Research together in Research & Development of new drugs “Made in Italy”
    Accelera announces the full accreditation by AAALAC International
    CHDI Foundation, Inc. and Siena Biotech S.p.A. enter collaboration to validate novel therapeutic targets for Huntington’s disease
    MolMed expands Phase III trial of NGR-hTNF for the treatment of mesothelioma in other European countries
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
  • 15 feb, 2011
    Sommario
    Biotechgate welcomes Assobiotec as co-partner for the Italian Biotech Database
    Orphan Drug Designation for Begedina 
    Abraxane available on the Italian market
    MolMed: Clinical Cancer Research publishes the results of a Phase I trial of NGR-hTNF in combination therapy with cisplatin
    FlyLife: genetic testing for health gain, now also in Europe
    BIO-Europe Spring 2011 returns to Milan, Italy
    BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
    Assobiotec visits Vienna and Innsbruck Life Science clusters
  • 01 feb, 2011
    Sommario
    Save the new date: BioInItaly Investment Forum 2011 & Intesa Sanpaolo Start-up Initiative to be held in Milan from April 4 to April 5, 2011
    MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
    DIESSE Ricerche and Toscana Biomarkers announce a R&D collaboration agreement
    Newron Pharmaceuticals raises CHF3.5m in a private placement
    Genovax completes the recruitment of the patients for the Phase I/II clinical study for GX301